Revenue Insights: Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Limited Performance Compared

Takeda's growth vs. Teva's challenges in pharma revenue.

__timestampTakeda Pharmaceutical Company LimitedTeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014177782400000020272000000
Thursday, January 1, 2015180737800000019652000000
Friday, January 1, 2016173205100000021903000000
Sunday, January 1, 2017177053100000022385000000
Monday, January 1, 2018209722400000018854000000
Tuesday, January 1, 2019329118800000016887000000
Wednesday, January 1, 2020319781200000016658000000
Friday, January 1, 2021356900600000015878000000
Saturday, January 1, 2022402747800000014925000000
Sunday, January 1, 2023426376200000015846000000
Monday, January 1, 2024426376200000016544000000
Loading chart...

Data in motion

Revenue Insights: Takeda vs. Teva

In the competitive landscape of the pharmaceutical industry, Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Limited have showcased contrasting revenue trajectories over the past decade. From 2014 to 2023, Takeda's revenue surged by approximately 140%, reflecting its strategic expansions and acquisitions. In contrast, Teva's revenue experienced a decline of around 22%, highlighting challenges in the generic drug market.

Takeda's Growth Story

Takeda's revenue growth, peaking at over 4.26 trillion yen in 2023, underscores its successful integration of Shire and a focus on specialty drugs. This growth trajectory positions Takeda as a formidable player in the global pharmaceutical arena.

Teva's Challenges

Teva, on the other hand, faced revenue contractions, with figures dropping to around 15.8 billion dollars in 2023. This decline is attributed to increased competition and pricing pressures in the generics sector.

The data reveals a tale of two companies navigating the complexities of the pharmaceutical industry with distinct strategies and outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025